Comparative in-vitro activity of twenty antimicrobial agents against clinical isolates of Mycobacterium avium complex. NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Comparative in-vitro activity of twenty antimicrobial agents against clinical isolates of Mycobacterium avium complex.

J Antimicrob Chemother. 1989 Nov;24(5):667-73. Unique Identifier : AIDSLINE MED/90094061
Khardori N; Rolston K; Rosenbaum B; Hayat S; Bodey GP; Department of Medical Specialities, University of Texas M. D.; Anderson Cancer Center, Houston 77030.

Abstract: The in-vitro susceptibility of Mycobacterium avium complex isolates, obtained from immunosuppressed patients with and without the Acquired Immunodeficiency Syndrome (AIDS), to various antimicrobial agents was determined. Amikacin, the 4-quinolone compounds--ciprofloxacin, temafloxacin and PD 117558--and the penem SCH 34343 were active against most of the isolates. In-vitro synergism using selected antimicrobial combinations could not be demonstrated. No differences in the susceptibility, depending upon the source of the isolates (AIDS or non-AIDS), were noted.
Keywords: Acquired Immunodeficiency Syndrome/MICROBIOLOGY Anti-Infective Agents/*THERAPEUTIC USE Comparative Study Culture Media Drug Synergism Human Microbial Sensitivity Tests Mycobacterium avium Complex/*DRUG EFFECTS Mycobacterium avium-intracellulare Infection/*MICROBIOLOGY JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/microbiologyanti-infectiveagents/KWDtherapeuticusecomparativestudyculturemediadrugsynergismhumanmicrobialsensitivitytestsmycobacteriumaviumcomplex/KWDdrugeffectsmycobacteriumavium-intracellulareinfection/KWDmicrobiologyjournalarticle
900430
M9040592

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .